CANADIAN CANCER TRIALS GROUP

ADVANCED PROSTATE

GU DISEASE ORIENTED GROUP MEETING AGENDA
CHELSEA HOTEL, TORONTO, ON
ROOM: WREN
SATURDAY APRIL 29TH, 2017, 8:00 AM – 9:00 AM

CO-CHAIRS: S. HOTTE & A. SO
SENIOR INVESTIGATOR: FRANCISCO VERA-BADILLO
STUDY COORDINATOR: ALEXANDER MONTENEGRO & P. STOS

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with advanced prostate cancer in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to advanced prostate cancer.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group and/or by national/international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to advanced prostate cancer.

8:00 am Welcome S. Hotte/ A. So

CCTG Open Trials

8:05 am IND.223: A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer K. Chi

8:10 am IND.232: A Phase II Study of Durvalumab (Medi4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer S. Hotte

CCTG Intergroup Closed trials

8:15 am PR.17/ANZUP 1304- ENZAMET Phase III testosterone suppression with or without Enzalutamide in first line metastatic prostate cancer S. North

continued on next page ...
CCTG Approved TRIALS

8:20 am IND234: Prostate cancer biomarker enrichment and treatment selection (pc-bets) study  
F. Vera-Badillo

TRIAL PROPOSAL UPDATES

8:30 am SWOG Randomized phase III trial of best standard therapy or best standard therapy plus definitive treatment (surgical resection or radiation) of the primary tumor in metastatic prostate cancer.  
K. Chi

8:35 am ECOG-ACRIN ERADICATE: Early Intervention after Radical Prostatectomy with Enzalutamide or Docetaxel versus Androgen Deprivation Therapy in Men at Highest Risk of Metastasis by Genomic Stratification.  
S. Hotte/ A. So

8:40 am PCS IX: The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: An Adaptive Phase II/III Randomized Trial  
T. Niazi

8:50 am Randomized Phase II Trial of Local Ablative Therapy for Hormone-Sensitive Oligometastatic Prostate Cancer  
P. Cheung

9:00 am Meeting adjourned